Justin R. Gregg, MD
Department of Urology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Adjunct Assistant Professor, Urology, Division of Cancer Prevention and Population Sciences, Houston, TX
Education & Training
Degree-Granting Education
| 2012 | Vanderbilt University School of Medicine, Nashville, Tennessee, US, MD |
| 2007 | Vanderbilt University College of Arts and Science, Nashville, Tennessee, US, Biological Sciences, BS |
Postgraduate Training
| 2022-null | Master of Public Health in Health Promotion and Health Education, UT School of Public Health, Houston, Texas |
| 2017-2019 | Clinical Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2017 | Clinical Residency, Urology, Vanderbilt University Medical Center, Nashville, Tennessee |
| 2013-2014 | Clinical Internship, General Surgery, Vanderbilt University Medical Center, Nashville, Tennessee |
Licenses & Certifications
| 2017 | American Board of Urology |
| 2017 | Texas State Board of Medical Examiners |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Health Disparities Research, Division of Cancer Prevention and Population Sciences, Houston, TX, 2020 - 2024
Assistant Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2024
Administrative Appointments/Responsibilities
Chief of Service, Urology, LBJ Urologic Oncology, Houston, Texas, 2026 - Present
Associate Site Director, Urology, UT Urology Residency Program MD Anderson Rotation, Houston, Texas, 2025 - Present
Medical Director, Urology, The MD Anderson Department of Urology New Prostate Patient Intake Clinic, Houston, TX, 2023 - Present
Committee Vice Chair, LBJ Multidisciplinary Genitourinary Tumor Board, Houston, TX, 2021 - Present
Other Professional Positions
Member, American Urological Association’s Research Council, 2025 - 2028
Head of Prostate Biopsy Working Group, University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present
Member, Harris Health Medical Staff Advisory Council, Houston, TX, 2023 - Present
Consultantships, Bayer, Houston, 2022 - Present
Harris Health Cancer Committee Quality Assurance & Performance Improvement Committee Member, Harris Health, Houston, TX, 2021 - Present
Director, UT Houston Urology Resident Research Program, Houston, TX, 2021 - 2026
Intramural Institutional Committee Activities
Co-Lead, Prostate Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2026
Member, Chair Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Extramural Institutional Committee Activities
Faculty Prostate Lead, Prostate Algorithm Group, The University of Texas MD Anderson Cancer Center, 2025 - Present
Project Team Leader, Prostate Cancer Demonstration Project, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Bylaws Committee, South Central Section of the AUA, 2025 - Present
Member, Health Equity Research and Practice Working Group, The University of Texas MD Anderson Cancer Center, 2023 - 2023
Leader, Department of Urology Journal Club, The University of Texas MD Anderson Cancer Center, 2023 - Present
Liason, Prostate Research Program Community Outreach and Engagement, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Harris Health Robotic Steering Committee Member, Harris Health, 2022 - Present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, Harris Health Cancer Committee Quality Assurance & Performance Improvement Committee, Harris Health, 2021 - 2025
Member, Data and Biospecimen Access Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2024
Editorial Activities
Section Editor, AUA Core Curriculum: Cancer Survivorship, 2025 - Present
Honors & Awards
| 2023 | Houston Methodist Collaborative Urology Research Symposium Appreciation Award |
| 2023 | Faculty Honoree, Community Outreach, UT MD Anderson |
| 2023 | Best Reviewer Award, Journal of Urology |
| 2022 | UT Houston Urology Resident Teaching Award |
| 2021 | Transdisciplinary Research in Energetics and Cancer Fellow |
| 2021 | AUA Early Career Investigator Showcase Finalist |
| 2019 | Bronze Reviewer Award, BJU International |
| 2018 | Recipient of the William L. Pippin, Jr. Fellowship in Genitourinary Research, The University of Texas at MD Anderson Cancer Center |
| 2017 | Second Place in Poster Competition, Society of Urology Oncology |
| 2015 | American Urological Association Southeastern Section Annual Quiz Bowl Co-Winner |
| 2011 | Alpha Omega Alpha Honor Society |
| 2007 | High Honors in Biological Sciences, Vanderbilt University College of Arts and Science |
| 2007 | Summa Cum Laude, Vanderbilt University College of Arts and Science |
| JU Open Plus Top Reviewer 2025, JU Open | |
| UT Houston Urology Resident Research Education Award, The University of Texas Houston | |
| AUA Young Urologist of the Year Award, American Urological Association |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Evaluating Prostate Cancer Biomarkers. MD Anderson Didactic Presentation. Invited. Urology Didactic Presentation. Houston, Texas, US.
- 2026. Houston Area Incubator KUH Research Opportunity, Research Elevator Pitch. Invited. 5th Annual Collaborative Urology Research Symposium (CUReS). Houston, Texas, US.
- 2026. Early Career Podium Session 1 – Urologic Oncology. Invited. 5th Annual Collaborative Urology Research Symposium (CUReS). Houston.
- 2026. Pre-surgical tirzepatide-assisted weight loss in overweight and obese men with intermediate risk prostate cancer: a pilot feasibility study. Poster. Houston Nutrition and Obesity Research Center 3rd Annual Research Symposium. Houston, Texas, US.
- 2026. Evaluating the effects of weight loss and diet change on a metabolism-related prostate cancer biomarker. Lightning Talk Podium Presentation. Poster. UT MD Anderson & UT Austin Collaborative Research Summit. Houston, Texas, US.
- 2026. LBJ Research and Resident Research Opportunities. Invited. UT Houston Urology Morning Conference. Houston, Texas, US.
- 2025. Future lifestyle interventions in active surveillance. Invited. Gallick Lab Seminar. Houston, Texas, US.
- 2025. Adaptation of the PREDIMED Intervention for Medically Underserved Prostate Cancer Patients through Intervention Mapping. Harris Health and UTHealth Houston Research and Quality Improvement Day. Poster. HH UT Research & Quality Improvement Day. Houston, TX, US.
- 2025. Determining Barriers to Dietary Change among Medically Underserved Men with Prostate Cancer. Harris Health and UTHealth Houston Research and Quality Improvement Day. Poster. HH UT Research & Quality Improvement Day. Houston, TX, US.
- 2025. PSA Screening. Invited. UT Houston Urology Grand Rounds. Houston, TX, US.
- 2025. Principal Investigator Breakout Session Leader. Invited. 2025 Houston Methodist Collaborative Urology Research Symposium. Houston, Texas, US.
- 2025. PSA Screening. Invited. Baylor College of Medicine Family Medicine Resident Didactics. Houston, TX, US.
- 2025. Clinical Trial Enrollment in the LBJ Urologic Oncology Clinic. Panelist. Advisory Council of Clinical Research Leaders. Houston, Texas, US.
- 2025. Low Testosterone and Grade Group Progression in Localized Prostate Cancer on Active Surveillance: A Retrospective Cohort Study. Poster. University of Texas 3rd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2024. PSA Screening for Prostate Cancer. Invited. Houston, Texas, US.
- 2024. Demographic and Treatment Differences Among Hispanic and Non-Hispanic Men with Testicular Cancer in a County Health System. Poster. Harris Health and UTH Research and Quality Improvement Day. Houston, Texas, US.
- 2024. A Mediterranean Diet-Based Behavioral Intervention For Men With Prostate Cancer. Poster. Harris Health and UTH Research and Quality Improvement Day. Houston, Texas, US.
- 2024. Evaluating the effects of weight loss and diet change on a metabolism-related prostate cancer biomarker. Invited. 2024 UT Austin & MD Anderson Collaborative Research Summit. Austin, Texas, US.
- 2024. Obesity, Dietary Quality and Localized Prostate Cancer Progression. Invited. Surgical Physician Assistant Continuing Education (S.P.A.C.E.). Houston, Texas, US.
- 2024. Evaluating Biomarkers for Prostate Cancer Screening. Houston, Texas, US.
- 2024. Urology Department Prostate Cancer Overview. Houston, Texas, US.
- 2024. Modifiable Prostate Cancer Risk Factors. Conference. St. Luke's United Methodist Church. Houston, TX, US.
- 2023. Challenges in patient and community-level translation: Reaching low SES and rural communities. Conference. The Center for Energy Balance in Cancer Prevention and Survivorship Day of Science. Houston, TX, US.
- 2023. Modifiable Prostate Cancer Risks. Conference. Methodist Hospital. Houston, TX, US.
- 2023. Developing a quality improvement project focused on consultation pathways at an academic center. Conference. Methodist Hospital. Houston, TX, US.
- 2023. Mediterranean diet pattern among men with localized prostate cancer. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2026. Benign but Burdensome: Management of Benign Prostatic Hyperplasia During Active Surveillance in a Large Cohort. Invited. South Central Section of the AUA. Tucson, AZ, US.
- 2026. Prostate Biopsy Yield Using Cognitive MRI Fusion Biopsy in a County Hospital. Invited. South Central Section of the AUA. Tucson, AZ, US.
- 2026. AUA PCA Guideline Updates (Localized, Advanced and Early Detection). Invited. Texas Urological Society Annual Meeting. Austin, Texas, US.
- 2026. Prostate (localized) Case Discussion. Panelist. 4th Annual Christopher G. Wood Advances in Urologic Oncology. Houston, Texas, US.
- 2025. Low Serum Testosterone Level and Biopsy Grade Group Progression Among Men With Prostate On Active Surveillance. Poster. South Central Section of the AUA. Orlando, FL, US.
- 2025. The Association Between Resting Heart Rate And Grade Group Progression In Men With Cancer On Active Surveillance. Poster. South Central Section of the AUA. Orlando, FL, US.
- 2025. Association Between Resting Heart Rate & Prostate Cancer Progression Among Men on Active Surveillance. Invited. Department of Surgery Research Day. Houston, TX, US.
- 2025. Resident Research Competition. Panelist. Department of Surgery Research Day. Houston, TX, US.
- 2024. Early Career Podium - Urologic Oncology. Session - Session Moderator. Conference. Houston Methodist Hospital, US.
- 2024. Clinical Trials: Will There Ever be an Effective Neoadjuvant Space?. Conference. UT MD Anderson Cancer Center. Austin, TX, US.
- 2023. Localized Prostate Cancer Biomarkers. Conference. UT MD Anderson Cancer Center. Austin, TX, US.
- 2022. Dietary Intervention in Intermediate Risk Prostate Cancer. Conference. Center for Energy Balance, UT MD Anderson Cancer Center, US.
- 2022. Small Focus of Gleason 7: Active Surveillance Podium Presentation. Conference. Texas Urological Society. Fort Worth, TX, US.
- 2022. Updates on Prostate Cancer Active Surveillance. Conference. Tex US TOO National Prostate Cancer and Education Support Group, US.
- 2021. Modifiable Prostate Cancer Risk Factors. Conference. Tex US TOO National Prostate Cancer and Education Support Group, US.
- 2021. Microbiome Research in Localized Prostate Cancer. Conference. UT MD Anderson Cancer Center, US.
- 2020. Managing Low/Intermediate Prostate Cancer. Conference. Tex US TOO National Prostate Cancer and Education Support Group, US.
- 2020. Prostate Biopsy Seminar Case Presentation Moderator. Conference. Genitourinary Malignancies Conference, US.
- 2019. Active for Surveillance for Localized Prostate Cancer. Conference. Cancer Network Integration, US.
- 2019. Management of Biochemical Relapse Post Radical Prostatectomy or Radiation Therapy. Conference. Management of Genitourinary Malignancies Conference, US.
National Presentations
- 2026. Survivorship After GU Cancer: The Consequences of Cure. Invited. Society for Urologic Oncology – Future Urologic Oncologists 2026 Meeting. Indianapolis, Indiana, US.
- 2026. Diet, Supplements, and False Hope: What Patients Ask and What We Should Say (From Mediterranean to Ivermectin). Invited. Society for Urologic Oncology – Future Urologic Oncologists 2026 Meeting. Indianapolis, Indiana, US.
- 2026. Neoadjuvant Therapy for High-Risk Prostate Cancer: Are We Finally Making Progress?. Invited. Society for Urologic Oncology – Future Urologic Oncologists 2026 Meeting. Indianapolis, Indiana, US.
- 2026. Prostate Cancer: Clinic to Community (and some stumbles along the way!. Invited. Transdisciplinary Research in Energetics and Cancer. Waterbury, Connecticut, US.
- 2026. Benign but Burdensome: Management of Benign Prostatic Hyperplasia During Active Surveillance in a Large Cohort. Poster. Society of Benign Prostatic Disease Meeting. Orlando, FL, US.
- 2026. Christopher Wood Memorial Case Presentations. Invited. 22nd Oncology Updates: Advances and Controversies. Steamboat, CO, US.
- 2025. Prostate Cancer Session 1: Active Surveillance for GG2 Prostate Cancer. Invited. 2025 Society of Urologic Oncology Meeting. Phoeniz, AZ, US.
- 2025. TREC Clinical Science Alumni Talk. Invited. Westbrook, CT, US.
- 2024. Prostate Cancer Block Moderator. Invited. South Central Section of the American Urological Association. Colorado Springs, CO, US.
- 2024. Panel participant for Rapid Prostate Cancer Cases. Invited. UT Christopher G. Wood Adv in Uro Onc Symposium. Austin, TX, US.
- 2023. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. Podium Presentation. Invited. Transdisciplinary Research on Energetics and Cancer Annual Meeting. Westbrook, CT, US.
- 2023. Prostate Cancer Imaging – A Urologist’s Perspective. Invited. SNMMI Southwest Chapter Annual Meeting. Sugarland, TX, US.
- 2022. American Institute for Cancer Research Plenary Talk: Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. Invited. American institute for cancer research. Leesburg, VA, US.
- 2022. Optimizing Sleep, Exercise, and Nutrition in Prostate Cancer. Invited. Answer Cancer Foundation, US.
- 2021. Prostate Cancer Board Review (podium). Invited. South Central Section of AUA, US.
- 2021. Prostate Biopsy Decisions – Advances that Improve Clinically Significant Detection and Reduce Complications (podium). Conference. South Central Section of the AUA, US.
- 2021. Moderated Poster: Association of Baseline Plasma Caffeine Levels and Related Metabolites with Time to Grade Group Progression in Men with Prostate Cancer on Active Surveillance. Invited. American Urological Association, US.
- 2021. Plenary: Panel Discussion: Negative Fusion Biopsy: What did I miss and what is the next step. Invited. American Urological Association meeting, US.
- 2020. Men on active surveillance for prostate cancer may benefit from Mediterranean diet. Conference. European Association of Urology Virtual Congress, US.
International Presentations
- 2024. Validation of a Blood-Based Sphingolipid Panel for Men with Prostate Cancer on Active Surveillance. Conference. European Association of Urology. Paris, FR.
- 2021. Screening Biomarkers, International Prostate Forum. Invited. American Urological Association, US.
- 2021. PSA Screening Panel Discussion, International Prostate Forum. Invited. American Urological Association meeting, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Evaluating Dietary Change and a Mediterranean Diet Intervention Among Medically Underserved Men with Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1K08CA293160-01A1 |
| Date: | 2024 - 2026 |
| Title: | Birdie for Buddies Prostate Research Grant |
| Funding Source: | Birdie for Buddies Prostate Research Grant |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Birdie for Buddies Prostate Research Grant |
| Funding Source: | Birdie for Buddies Foundation |
| Role: | PI |
| Date: | 2023 - 2024 |
| Title: | UT-Austin/MDACC Collaborative Pilot Project Grants |
| Funding Source: | University of Texas- Austin |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | An evidence-based focal cryotherapy protocol for focal ablation of intermediate risk prostate cancer |
| Funding Source: | Prioritizing Research Innovation and Mentoring Excellence (PRIME) |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Determining dietary habits and prostate cancer biomarkers for use in dietary intervention studies among underserved men with prostate cancer at LBJ Hospital |
| Funding Source: | Duncan Family Institute Seed Grant |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Coffee and Caffeine Metabolites and Disease Progression in Men Enrolled on Active Surveillance for Prostate Cancer |
| Funding Source: | American Institute for Cancer Research (AICR) |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Expanding a metabolomics-based marker of prostate cancer progression for use in future clinical trials |
| Funding Source: | Duncan Family Institute Seed Grant |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Principal Investigator, Non-invasive metabolomics-based prostate cancer markers: effect of dietary and surgical intervention, Institutional Research Grant |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | Investigating the use of a plasma-based sphingolipid signature and dietary change in patients with localized prostate cancer managed with active surveillance |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | P50 CA140388 |
| Date: | 2018 - 2022 |
| Title: | DOD, CDMRP, Prostate Cancer Research Program, Early Career Investigator Award Proteomic-based Biomarkers for Risk of Progression in Early Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | PC171067 |
Selected Publications
Peer-Reviewed Articles
- Najdi J, Gregg JR. Editorial Comment. J Urol:101097JU0000000000005282, 2026. e-Pub 2026. PMID: 42715410.
- Monaco A, Koh S, Guo A, Garcia RS, Ellis T, Palasi S, Lawen T, da Silva RD, Gregg JR. Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort. Urol Oncol, 2026. e-Pub 2026. PMID: 42557189.
- Rooney M, Patel KR, Shah S, Gregg JR, Jay Frank S, Hoffman K, Park R, Hassanzadeh CJ, Choi S, McGuire S, Nguyen QN, Costa DN, Troncoso P, Subudhi SK, Zhao SG, Pettaway CA, Corn P, Tang C, Tran PT. Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer. CA Cancer J Clin 76(4):e70105, 2026. e-Pub 2026. PMID: 42638189.
- Chapin BF, Smaldone M, Zurita AJ, Wang J, Cooperberg MR, Gleave M, Delacroix SE, Davis J, Pettaway C, Pisters L, Adibi M, Chery L, Papadopoulos J, Ward J, Gregg J, Navai N, Corn P, Subudhi SK, Logothetis C, Kuban D, Nguyen Q, Tang C, Choi S, Hoffman K, Lozano M, Elsheftawi M, Achim M, Zhao Y, Ramesh N, Sei E, Navin N, Nogueras Gonzalez GM, Wang X, Zhu K, Troncoso P, Zhang M, McGuire S, Aparicio AM. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol, 2026. e-Pub 2026. PMID: 41833492.
- Smith M, Garcia R S, Cho D, Tariba-Edick M, Lawen T, Daniel C, McNeill L, Pettaway C, Gregg JR. Determining Barriers to Dietary Change Among Medically Underserved Men With Prostate Cancer. PubMed, 2026. e-Pub 2026. PMID: 41738325.
- Lawen T, Garcia RS, Smith MT, Pyo J, Higgason NM, Robert MJM, Chapin BF, Chery LS, Davis JW, Ward JF, Pisters LL, Pettaway CA, Hahn AW, Frigo DE, Wei P, Daniel CR, Gregg JR. Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study. J Urol:101097JU0000000000004986, 2026. e-Pub 2026. PMID: 41662578.
- Garcia RS, Daniel CR, Hwang C, Levy E, Smith M, Cho D, Frigo DE, Hahn AW, Ma H, Robert M, Pettaway C, Chapin BF, LaRue D, Canfield S, Wargo J, Wei P, McNeill L, Gregg JR. Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients. Transl Behav Med 16(1), 2026. e-Pub 2026. PMID: 42258524.
- Venkatesh, N, Chauhan, PK, Mukhida, SS, Grewal, K, Aparicio, A, Pilie, PG, Subudhi, SK, Corn, P, Sachdeva, A, Desai, M, Siddiqui, BA, Zurita-Saavedra, A, Pain, D, Gregg, JR, Frigo, DE, Logothetis, CJ, Msaouel, P, Koutroumpakis, E, Hahn, AW. Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy. JCO Oncology Practice, 2025. e-Pub 2025. PMID: 41202201.
- Smith M, Lawen T, Garcia RS, Pyo J, Hahn A, Frigo D, Ma H, Wei P, Robert M, Chery L, Chapin BF, Daniel CR, Pettaway C, Gregg JR. The intersection of race and adiposity in prostate cancer: a narrative review. Eur J Cancer Prev, 2025. e-Pub 2025. PMID: 41117610.
- Leonard, Alex, Pettaway, Curtis, Pisters, Louis, Davis, John, Papadopoulos, John, Chery, Lisly, Garcia, Rebekka, Chen, Jiansong, Daniel Carrie, Troncoso, Patricia, Wei, Peng, Chapin, Brian, Gregg JR. Grade Group 1 Core Volume at Time of Biopsy Is Not Associated With Rate of Adverse Pathology at Radical Prostatectomy. JU Open Plus 3(9):e00106, 2025. e-Pub 2025.
- Landan P, Choi, Christine, Alberto, Irene A, Abhi, Justin R, John F. Is Confirmatory Prostate Biopsy Necessary in Active Surveillance Patients With an Initial Magnetic Resonance Imaging Ultrasound Fusion Biopsy?. JU Open Plus, 2025. e-Pub 2025.
- Garcia R, Daniel C, Hwang C, Levy E, Smith M, Cho D, Frigo D, Hahn A, Ma H, Robert M, Pettaway C, Chapin B, LaRue D, Canfield S, Wargo J, Wei P, McNeill L, Gregg JR. Adaptation of the PREDIMED Intervention for Medically Underserved Prostate Cancer Patients Through Intervention Mapping. medRxiv, 2025. e-Pub 2025. PMID: 41738325.
- McKay RR, Ross AE, Preston MA, Gregg JR, Salami SS, Littleton N, Constantinovici N, Srinivasan S, Verholen F, Shore ND. Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. Future Oncol 21(11):1-11, 2025. e-Pub 2025. PMID: 40165634.
- Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12), 2024. e-Pub 2024. PMID: 39324992.
- Gregg, JR, Newcomb, LF, Wu, R, Dennison, JB, Davis, JW, Pettaway, CA, Pisters, L, Ward, JF, Chapin, BF, Chery, LJ, Urkmez, A, Fang, A, Higgason, N, Troncoso, P, Daniel-MacDougall, CR, Logothetis, CJ, Thompson, TC, Hahn, AW, Liu, M, Zheng, Y, Lin, DW, Hanash, SM, Irajizad, E, Fahrmann, JF. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 39522029.
- Palasi SF, Rivas A, Owen CK, Rajendran R, Macias J, Gregg J, McCarty M, da Silva RD. The financial impact of delays to percutaneous nephrolithotomy surgery at a county hospital. UroPrecision, 2024. e-Pub 2024.
- Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. e-Pub 2024. PMID: 39019979.
- Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. e-Pub 2024. PMID: 38837608.
- Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Rais-Bahrami S, Bathala T, Chapin BF. Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol 25(5):617-618, 2024. e-Pub 2024. PMID: 38642282.
- Fang AM, Gregg JR. Editorial Comment. J Urol 211(4):563, 2024. e-Pub 2024. PMID: 38299558.
- Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Chéry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
- Gregg JR, Kim J, Logothetis C, Hanash S, Zhang X, Manyam G, Muir K, Group UC, Giles GG, Stanford JL, Berndt SI, Kogevinas M, Brenner H, Eeles RA, Consortium P, Wei P, Daniel CR. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. Eur Urol Oncol 6(3):282-288, 2023. e-Pub 2023. PMID: 35995710.
- Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol, 2022. e-Pub 2022. PMID: 36082549.
- Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv 3(1), 2022. e-Pub 2022. PMID: 34993496.
- Shapiro DD, Davis JW, Williams WH, Chapin BF, Ward JF, Pettaway CA, Gregg JR. Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. BJUI Compass, 2022. e-Pub 2022. PMID: 35475154.
- Tan, WP, Rastinehad, A, Klotz, L, Carroll, P, Emberton, M, Feller, JF, George, AK, Gill, IS, Gupta, RT, Katz, AE, Lebastchi, AH, Marks, LS, Marra, G, Pinto, PA, Song, DY, Sidana, A, Ward, JF, Sanchez-Salas, R, Rosette, Jl, Polascik, TJ, Katz, AE, Aminsharifi, A, Lebastchi, AH, Abreu, A, Villers, A, Schulman, A, Rastinehad, A, George, A, Oto, A, Turkbey, B, Malavaud, B, Muller, BG, Moore, CM, Eberli, D, Margolis, D, Song, D, Lomas, D, Orabi, H, Lepor, H, Tan, HM, Jambor, I, De La Rosette, JJ, Grummet, J, Feller, JF, Ward, J, Colemen, J, Gregg, JR, Tay, KJ, Marks, LS, Deane, L. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations 39(11):781.e17-781.e24, 2021. e-Pub 2021. PMID: 33676851.
- Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg S, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol, 2021. e-Pub 2021. PMID: 34503355.
- Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg S, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol, 2021. e-Pub 2021. PMID: 34503355.
- Gregg JR, Borregales LD, Choi H, Lozano M, McRae SE, Venkatesan AM, Davis JW, Nogueras-Gonzalez GM, Pisters LL, Ward JF. Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World J Urol 39(9):3259-3264, 2021. e-Pub 2021. PMID: 33454813.
- Cho D, Milbury K, Liao Y, Pettaway CA, Gregg JR, Li Y, McNeill LH. Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners. PLoS One, 2021. e-Pub 2021. PMID: 34370761.
- Geskin AA, Westney O, Graber WJ, Thomas G Smith III, Chapin BF, Gregg JR. Complications Of Peri-Operative Ureteral Catheter Placement: Experience at A Major Cancer Center. J Urol. e-Pub 2021. PMID: 34280440.
- Chang CM, McIntosh AG, Shapiro DD, Davis JW, Ward JF, Gregg JR. Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?. BJUI Compass, 2021. e-Pub 2021. PMID: 35475129.
- Urkmez A, Ward JF, Choi H, Troncoso P, Inguillo I, Gregg JR, Altok M, Demirel HC, Qiao W, Kang HC. Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy. BJU Int 127(5):524-527, 2021. e-Pub 2021. PMID: 33340435.
- Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology. e-Pub 2021. PMID: 33676955.
- Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer 127(5):720-728, 2021. e-Pub 2021. PMID: 33411364.
- Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int 127(3):340-348, 2021. e-Pub 2021. PMID: 32357283.
- Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW. The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance. J Urol 205(1):101097JU0000000000001321, 2021. e-Pub 2021. PMID: 32718204.
- Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus 7(1):71-77, 2021. e-Pub 2021. PMID: 31076357.
- Cho D, Basen-Engquist K, Acquati C, Pettaway C, Ma H, Markofski M, Li Y, Canfield SE, Gregg J, McNeill LH. Cultural Adaptation of Evidence-Based Lifestyle Interventions for African American Men With Prostate Cancer: A Dyadic Approach. Am J Mens Health, 2020. e-Pub 2020. PMID: 33148111.
- Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun 11(1):4279, 2020. e-Pub 2020. PMID: 32855410.
- Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology 138:91-97, 2020. e-Pub 2020. PMID: 31899230.
- Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, Kim J. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. National Review of Clincal Oncology, 2019. e-Pub 2019. PMID: 30413793.
- Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance. J Urol 201(2):308-314, 2019. e-Pub 2019. PMID: 30179617.
- Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CR. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer 120(4):466-471, 2019. e-Pub 2019. PMID: 30679782.
- Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW, Thompson TC, Kim J, Logothetis CJ, Wu X. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer and disease reclassification in active surveillance cohort. Oncoimmunology 8(1):e1483303, 2019. e-Pub 2019. PMID: 30546938.
- Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol 74(2):140-143, 2018. e-Pub 2018. PMID: 29656854.
- Gregg JR, Bhalla RG, Cook JP, Kang C, Dmochowski R, Talbot TR, Barocas DA. An Evidence-Based Protocol for Antibiotic Use Prior to Cystoscopy Decreases Antibiotic Use without Impacting Post-Procedural Symptomatic Urinary Tract Infection Rates. J Urol 199(4):1004-1010, 2018. e-Pub 2018. PMID: 29108916.
- Tyson MD, Ark J, Gregg JR, Johnsen NV, Kappa SF, Lee DJ, Smith JA. The Null Effect of Bladder Neck Size on Incontinence Outcomes After Radical Prostatectomy. J Urol 98(6):1404-1408, 2017. e-Pub 2017. PMID: 28655528.
- Gregg JR, Kang CL, Talbot TR, Moore D, Herrell SD, Dmochowski R, Barocas DA. Symptomatic Urinary Tract Infections in Renal Transplant Patients After Cystoscopy for Ureteral Stent Removal. Urol Pract 4(5):405-411, 2017. e-Pub 2017. PMID: 29250578.
- Gregg JR, Lang M, Wang LL, Resnick MJ, Jain SK, Warner JL, Barocas DA. Automating the Determination of Prostate Cancer Risk Strata From Electronic Medical Records. JCO Clin Cancer Inform 1:1-8, 2017. e-Pub 2017. PMID: 29541700.
- Gregg JR, Emeruwa C, Wong J, Barocas DA, Chang SS, Clark PE, Cookson MS, Penson DF, Resnick MJ, Scarpato KR, Smith JA, Moses KA. Oncologic Outcomes After Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. J Urol 196(4):1030-5, 2016. e-Pub 2016. PMID: 27164514.
- Gregg JR, McCormick B, Wang L, Cohen P, Sun D, Penson DF, Smith JA, Clark PE, Cookson MS, Barocas DA, Resnick MJ, Moses KA, Chang SS. Short Term Complications from Trans-Urethral Resection of Bladder Tumor. Can J Urol 23(2):8198-8203, 2016. e-Pub 2016. PMID: 27085823.
- Gregg JR, Lai C, Dmochowski R, Talbot T, Barocas DA. Recent Antibiotic Treatment Increases the Risk of Post-Outpatient Cystoscopy Urinary Tract Infection. Urology Practice 2(3):90-96, 2016. e-Pub 2016.
- Nottingham CU, Patel SG, Clark PE, DeGraff DJ, Gregg JR, Anderson BB, Paner GP, Steinberg GD, and Vander Griend DJ. SOX2 Expression in Patients who Underwent Radical Cystectomy for Urothelial Carcinoma of the Bladder. Clinics in Oncology 1:1022, 2016. e-Pub 2016.
- Gregg JR, Horn L, Davidson MA, Gilbert J. Patient Enrollment onto Clinical Trials: the Role of Physician Knowledge. J Cancer Educ 29(1):74-79, 2014. e-Pub 2014. PMID: 24163050.
- Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA. Effect of Preoperative Nutritional on Mortality After Radical Cystectomy for Bladder Cancer. J Urol 185(1):90-96, 2011. e-Pub 2011. PMID: 21074802.
- Aghazadeh MA, Barocas DA, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA, Chang SS. Determining Factors for Hospital Discharge After Radical Cystectomy in a large Contemporary Cohort. Journal of Urology 185:85-89, 2011. e-Pub 2011. PMID: 21074199.
- Morgan TM, Tang D, Straton K, Barocas DA, Anderson C, Gregg JR, Change SS, Cookson MS, Herrell HD, Smith JA, Clark PE. Pre-operative Nutritional Status is an Important Predictor of Survival Following Surgery for Renal Cell Carcinoma. European Urology 59:923-928, 2011. e-Pub 2011.
- Gregg JR, Herring NR, Naydenov AV, Hanlin RP, Konradi C. Downregulation of oligodenrocyte transcripts is associated with impaired prefrontal cortex function in rats. Schizophr Res 113(2-3):277-287, 2009. e-Pub 2009. PMID: 19570651.
Invited Articles
- Gregg JR, Thompson TC. Considering the potential for gene-based therapy in prostate cancer. Nature Reviews Urology, 2021. e-Pub 2021. PMID: 33637962.
- Gregg JR, Chang SS. Blue-light and Narrow Band Imaging in the Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. AUA Update Series, 2017. e-Pub 2017.
- Gregg JR, Chang SS. Treatment of muscle-invasive bladder cancer. Evidence-Based Urology. Wiley, 2017. e-Pub 2017.
- Gregg JR, Scarpato KR. Surgical Approaches for Open Renal Surgery, Including Open Radical Nephrectomy. Hinman’s Atlas of Urologic Surgery, 2017. e-Pub 2017.
- Gregg JR, Dahm P, Chang SS. Guideline-based management of non-muscle invasive bladder cancer. Indian J Urol 31(4):320-326, 2015. e-Pub 2015. PMID: 26604443.
Review Articles
- Fang A, Frigo DE, Hahn A, Razouki Z, Hwang J, Koutroumpakis E, Lawen T, Smith M, Hamilton-Reeves J, DiGiovanni J, Higgason N, Garcia RS, Chapin BF, Pettaway C, Chery L, Troncoso P, Logothetis C, Daniel CR, Wei P, Gregg JR. GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials. Urology 201:152-158, 2025. e-Pub 2025. PMID: 40348027.
- Fang, A, MacDonald, LP, Gregg, JR, Siddiqui, BA, Tang, C, Chapin, BF. Prostatectomy and other local treatments for oligometastatic prostate cancer. Current opinion in urology 35(2):171-177, 2025. e-Pub 2025. PMID: 39604252.
- Fang, A, Gregg, JR, Pettaway, CA, Ma, J, Szklaruk, J, Bathala, TK, Surasi, DS, Chapin, BF. Whole-body MRI for staging prostate cancer. BJU International 135(1):13-21, 2025. e-Pub 2025. PMID: 39308142.
- Venkatesh, N, Tidwell, R, Yu, Y, Aparicio, A, Zurita-Saavedra, A, Subudhi, SK, Siddiqui, BA, Gregg, JR, Corn, P, Msaouel, P, Koutroumpakis, E, McQuade, JL, Frigo, DE, Pilie, PG, Logothetis, CJ, Huff, C, Hahn, AW. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC). Journal of Clinical Oncology 42:108, 2024. e-Pub 2024.
- Fang, A, Jackson, J, Gregg, JR, Chery, LJ, Tang, C, Surasi, DS, Siddiqui, BA, Soroush-Rais-Bahrami, Bathala, TK, Chapin, BF. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Current treatment options in oncology 25(1):66-83, 2024. e-Pub 2024. PMID: 38212510.
- Gregg JR, Thompson TC. Considering the potential for gene-based therapy in prostate cancer. Nat Rev Urol 18(3):170-184, 2021. e-Pub 2021. PMID: 33637962.
Other Articles
- Magill, RG, Gregg, JR Editorial Commentary. Urology Practice 9(5):420-421, 2022. PMID: 37145756.
Editorials
- Fang, A, Gregg, JR. Editorial Comment. Journal of Urology 212(1):29, 2024.
- Lim A, Gregg JR. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology, 2020. PMID: 32459977.
- Gregg JR. Adherence to AUA Guidelines for Periprocedural Antibiotics for In-Office Cystoscopy after Implementation of a Simple Quality Improvement Protocol. American Urological Association, 2020.
- Shapiro DD, Gregg JR. Antibiotic Stewardship for Ambulatory Urological Procedures: Cystoscopy and Vasectomy. American Urological Association, 2020.
- Lim A, Gregg JR. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Journal of Urology, 2020.
- Gregg JR. Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate Cancer 4(2):e00023, 2006.
Abstracts
- Hwang JP, Zhang N, Misoi M, Gull S, Razouki Z, Gregg JR, Giordano SH. Effect of metabolic syndrome on survival among patients with breast or prostate cancer, 2025.
- Palasi S, MD, Kim D, Mehr J, Owen C, Gregg J, MD, McCarty M, MD. Delays in Percutaneous Nephrolithotomy Surgery: Impact on Postoperative Outcomes Among Patients Treated at a County Hospital, 2023. e-Pub 2023.
- Leonard A, Troncoso P, Chapin BF, Pisters L, Pettaway C, Davis JW, Ward JF, Papadopoulos J, Adibi M, Chery L, Gregg JR. Including Grade Group 1 Disease in national comprehensive Cancer Network Risk Stratification for unfavorable intermediate risk disease may not effect rates of adverse pathology following radical prostatectomy. Methodist Collaborative Urology Research Symposium, 2023. e-Pub 2023.
- Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Chéry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso P. Association of Body Mass Index with Tumor Zonal Origin and Pathologic Features at Radical Prostatectomy. Society of Urologic Oncology, 2022. e-Pub 2022.
- Shapiro D, MD, Ward J, FACS MD, Lim A, PhD MD, Nogueras-Gonzalez G, MPH, Chapin B, MD, Davis J, FACS MD, Gregg J, MD. COMPARING CONFIRMATORY BIOPSY OUTCOMES BETWEEN MRI-TARGETED BIOPSY AND STANDARD SYSTEMATIC BIOPSY AMONG MEN BEING ENROLLED IN PROSTATE CANCER ACTIVE SURVEILLANCE. MD1 South Central section AUA, 2022. e-Pub 2022.
- Shore ND, Preston MA, Gregg JR, Salami SS, Ross A, Bruno A, Srinivasan S, Constantinovici N, Ortiz JA, Verholen F, McKay RR. Open-label study of Androgen Receptor inhibition with dArolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-Sensitive prostate cancer (mHSPC) using an External Control arm (ARASEC). 2022 ASCO Annual Meeting I, 2022. e-Pub 2022.
- Borregales LD, Gregg J, Choi H, Lozano M, McRae SE, Aradhana M, Venkatesan, Davis JW, Munsell MF, Nogueras-Gonzalez GM, Achim M, Sampatrao S, Pisters LL, Ward JF. Prospective trial of regional (hockey-stick) prostate cryoablation: 7-year Pathologic and Quality of Life outcomes. American Urological Association, 2022. e-Pub 2022.
- Cass S, Wargo J, Pettaway C, Pisters L, Davis J, Chapin B, Ward J, Daniel C, Gregg JR. A Novel Mediterranean Dietary Intervention for Prostate Cancer. 2022 AACR, 2022. e-Pub 2022.
- Marra G, Laguna MP, Walz J, Pavlovich CP, Gregg FB, Lebastchi AH, Lepor H, Macek P, Rais-Bahrami S, Robertson C, Rukstalis D, Salomon G, Ukimura O, Abreu AL, Barbe Y, Cathelineau X, Gandaglia G, George AK, Rivas JG, Gupta RT, Lawrentschuk N, Kasivisvanathan V, Lomas D, Malavaud B, Margolis D, Matsuoka Y, Mehralivand S, Moschini M, Oderda M, Orabi H, Rastinehad AR, Remzi M, Schulman A, Shin T, Shiraishi T, Sidana A, Shoji S, Stabile A, Valerio M, Tammisetti VS, Tan WP, DEN Bos WV, Villers A, Willemse P, LA Rosette JD, Polascik T, Sanchez-Salas R, Society FT. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. Minerva Urology Nephrology, 2021. e-Pub 2021. PMID: 33439577.
- Urkmez A, Gregg JR, Davis JW. Courtney Chang, MD1,2, Andrew McIntosh, MD2, John Davis, MD2, John Ward, MD2, Justin Gregg, MD. South Central section AUA, 2020. e-Pub 2020.
- Urkmez A, Gregg JR, Courtney Chang JWD, MD, McIntosh A, MD, Davis J, MD, Ward J, MD, Gregg J, MD. Determining the Sensitivity and Specificity of Preoperative MRI on Post-Operative Upgrading in Men with Low-Risk Prostate Cancer. South Central Section AUA, 2020. e-Pub 2020.
- Chang C, MD, McIntosh A, MD, Davis J, MD, Ward J, MD, Gregg J, MD. Does a Screening Digital Rectal Exam Provide Actionable Clinical Utility in Patients with Already Known Elevated PSA and Positive MRI?. South Central Section AUA, 2020. e-Pub 2020.
- Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, Kim J. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. National Review of Clinical Oncology, 2019. e-Pub 2019.
- Gregg JR, Reichard C, Wang X, Chapin BF, Pisters L, Pettaway C, Ward J, Achim M, Choi S, Kuban D, Davis J, Kim J. Improving risk-stratification of localized prostate cancer in a prospective active surveillance cohort. American Society of Clinical Oncology Genitourinary Cancer Symposium, 2018. e-Pub 2018.
- Gregg JR, Fahrmann, J, Peterson C, Dhillon D, Vykoukal J, Dennison J, Hanash S, Davis J, Kim J, Thompson T. Proteomic-Based Biomarkers for Risk of Progression in Early Prostate Cancer. Society of Urologic Oncology, 2017. e-Pub 2017.
- Gregg JR, Emeruwa C, Wong J, Barocas DA, Chang SS, Clark PE, Cookson MS, Penson DF, Resnick MJ, Scarpato KR, Smith JA, and Moses KA. Oncologic Outcomes After Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. Southeastern Section of the American Urological Association annual meeting, 2015. e-Pub 2015.
- Gregg JR, Lang M, Wang LL, Warner JL, and Barocas DA. The Use of Natural Language Processing in Determining Prostate Cancer Risk Strata. Southeastern Section of the American Urological Association annual meeting, 2015. e-Pub 2015.
- Gregg JR, Bush WS, Clark PE. The Affect of PSA-Associated Single Nucleotide Polymorphisms on African American Male PSA Values. Clinical Congress of the American College of Surgeons, 2015. e-Pub 2015.
Web Publications
- Sandra Gordon. At-home Prostate Cancer Test May Help Some Men Avoid Biopsy.
- Fang A, Frigo DE, Hahn A, Razouki Z, Hwang J, Koutroumpakis E, Lawen T, Smith M, Hamilton-Reeves J, DiGiovanni J, Higgason N, Garcia RS, Chapin BF, Pettaway C, Chery L, Troncoso P, Logothetis C, Daniel CR, Wei P, Gregg JR. GLP-1 Agonist Use Among Men with Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials - Beyond the Abstract.
Patient Reviews
CV information above last modified September 14, 2026